Gilead Sciences (GILD) Misses Q3 EPS by 11c; Reiterates Outlook

November 1, 2016 4:03 PM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Gilead Sciences (NASDAQ: GILD) reported Q3 EPS of $2.75, $0.11 worse than the analyst estimate of $2.86. Revenue for the quarter came in at $7.4 billion versus the consensus estimate of $7.45 billion.Gilead Sciences reaffirmed FY2016 guidance.

Full Year 2016 Guidance Reiterated

Gilead reiterates its full year 2016 guidance, as revised on July 25, 2016:

(In millions, except percentages and per share amounts) Updated July 25, 2016

Reiterated November 1, 2016

Net Product Sales $29,500 - $30,500
Non-GAAP*
Product Gross Margin 88% - 90%
R&D Expenses $3,600 - $3,800
SG&A Expenses $3,100 - $3,300
Effective Tax Rate 18.0% - 20.0%
Diluted EPS Impact of Acquisition-related, Up-front Collaboration, Stock-based Compensation and Other Expenses $1.47 - $1.53

For earnings history and earnings-related data on Gilead Sciences (GILD) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Earnings, Guidance

Related Entities

Earnings

Add Your Comment